The IPOX® Watch - Cerevel Therapeutics

Company Description

Founded in 2018, Cerevel Therapeutics Holdings, Inc is a clinical-stage biopharmaceutical company that focuses on neuroscience diseases headquartered in Cambridge, MA. Cerevel Therapeutics has four lead programs that target schizophrenia, epilepsy, and Parkinson’s disease, respectively. Bain Capital and Pfizer own, collectively, ca. 59.6% of the company.   

Business Model

Cerevel Therapeutics has not generated any revenue from product sales to date.

Reverse Merger IPO History

On 10/28/2020, Cerevel Therapeutics Holdings Inc completed business combination with the special purpose acquisition company ARYA Sciences Acquisition Corp II (Arya II) and began trading on the Nasdaq Capital Market. The merger was first announced on 7/29/2020. Cerevel Therapeutics fell on first day to $9.88 (▼2.18%).

Cerevel Therapeutics Holdings, Inc was included in the IPOX® 100 U.S. Index (ETF: FPX US, FPX LN) on 09/20/2021 and currently weighs ca. 0.20% of the portfolio.                                                                        

Click to download the PDF